Introduction
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. In this lethal disorder, there is widespread deposition of amyloid fibrils, derived from monoclonal immunoglobulin light chains associated with an underlying clonal plasma cell dyscrasia. Amyloid deposits progressively damage multiple organs and tissues. The median survival of untreated patients is 13 months from diagnosis and is increased marginally to 16-18 months when patients are treated with oral low-dose cyclic melphalan and prednisone treatment. 1, 2 However, this form of treatment rarely results in eradication of the underlying plasma cell dyscrasia or reversal of organ dysfunction. In contrast, high-dose melphalan and stem cell transplantation (HDM/SCT) can induce hematologic and clinical remissions and prolong survival substantially. 3 Our experience treating more than 300 patients suggests that clinical outcomes following HDM/SCT correlate with the attainment of a hematologic complete response (HCR), 3 that is whether the underlying monoclonal gammopathy and clonal plasma cell dyscrasia is eliminated. We have found that the median survival of patients who achieve an HCR is 48 years compared to 5.2 years for those who do not 3 and that clinical improvement in affected organ systems occurs in 2/3 of patients achieving an HCR compared to only 1/3 of those who do not. There are similar differences with respect to improvements in performance status 3 and quality of life. 5 Because HCR is such a critical determinant of treatment outcome following HDM/SCT, we questioned whether tandem cycles of treatment might increase the proportion of patients who ultimately achieve an HCR. Experience with tandem cycles of high-dose chemotherapy in myeloma have shown that HCR increases following tandem cycles of treatment. 4 Moreover, event-free survival and overall survival have been reported to be superior for tandem cycles of treatment. 6 These considerations prompted us to conduct a prospective trial of tandem cycles of HDM/SCT for the treatment of AL amyloidosis. The objective of this trial was to determine whether a second cycle of HDM/ SCT could induce an HCR in patients in whom the plasma cell dyscrasia persisted following initial treatment with HDM/SCT. Additional objectives of the trial were to evaluate the feasibility and tolerability of tandem cycles of this aggressive treatment and survival in AL amyloidosis.
Patients and methods

Eligibility criteria
This clinical trial was approved by the Institutional Review Board of the Boston University Medical Center in accordance with federal regulations and the Declaration of Helsinki. Eligibility for the study required a tissue diagnosis of amyloidosis with evidence of an underlying clonal plasma cell dyscrasia as indicated by an abnormal clonal dominance of plasma cells in the BM and/or detection of a monoclonal gammopathy by immunofixation electrophoresis of serum and urine proteins and/or an abnormal serum free light chain ratio. Patients were required to be less than 65 years of age. Previous nontransplant treatment for AL amyloidosis was allowed but the cumulative dose of the earlier oral melphalan could not exceed 300 mg. Other eligibility criteria included a Southwest Oncology Group performance status score of o2, left ventricular ejection fraction445% and diffusion capacity (DLCO)450%. Patients requiring dialysis for end-stage renal disease were not excluded if other eligibility criteria were met.
Treatment protocol
PBSCs were collected by leukaphersis following G-CSF mobilization, and a minimum yield of 7.5 Â Following the first cycle of treatment, patients were evaluated for hematologic response at 6 months. Patients who had evidence of a persistent plasma cell dyscrasia and who had not experienced grade 4 non-hematologic toxicities during the first cycle of HDM/SCT received a second cycle of modified high-dose i.v. melphalan (140 mg/ m 2 ) followed by autologous transplant of their cryopreserved stem cells, within 6-12 months of the first cycle.
All patients were followed for hematologic and clinical responses.
Toxicity and response criteria
The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3, was used to grade adverse events. The response criteria for hematologic and clinical/organ response used were standards defined by the consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. 7 An HCR 3 was defined as absence of monoclonal protein in serum and urine by immunofixation electrophoresis, a normal BM biopsy with less than 5% plasma cells and absence of k or l clonal predominance by immunohistochemistry and a normal serum immunoglobulin free light chain ratio. Clinical/organ responses were defined as per the consensus report from the 10th International Symposium on Amyloid and Amyloidosis. 7 At the time this study began, measurement of serum-free immunoglobulin light chains was not available at our institution or commercially, and this assay was not used for eligibility or response determination for all patients.
Design and statistical analysis
The primary analysis was a test of the null hypothesis that 50% of subjects with greater than 7.5 Â 10 6 CD34 þ cells/ kg at stem cell mobilization and collection ultimately experienced HCR upon completion of treatment. The HCR percentage of 50% is based on experience with earlier protocols that did not involve tandem cycles of HDM/SCT. Only those subjects with greater than 7.5 Â 10 6 CD34 þ cells/kg at stem cell mobilization and collection were included in the primary analysis. We expected that 80% of patients would have desirable stem cell yield at stem cell mobilization and collection. Thus our accrual goal of 62 subjects was anticipated to yield 49 patients eligible for tandem cycles of HDM/SCT. Assuming an HCR rate of 70% with tandem cycles of HDM/SCT, this sample size was expected to provide 80% power using a two-sided exact binomial test and an a level of 0.05 to reject the null hypothesis of an HCR rate of 50% in favor of the alternative of 70%.
A comparison of survival was carried out with a control cohort, similar in age, number of organ involvement, presence and severity of cardiac involvement who had been 
Results
Patient characteristics
From November 2000 to June 2005, 62 patients with AL amyloidosis were enrolled on the trial, before stem cell collection. The median age of enrolled patients was 55.5 years (range 32-65). There were 40 men and 22 women enrolled. Among enrolled patients, 51 (82%) had a l-and 11 (18%) a k-clonal plasma cell dyscrasia. The distribution of organ involvement was typical for AL amyloidosis: 18 patients (29%) had isolated renal involvement; 25 (40%) had cardiac involvement and 27 (44%) had greater than two organ systems involved. Ten patients had serum creatinine X2.0 mg/dl (median: 2.8 mg/dl, range: 2.0-4.5 mg/dl). Two other patients were on hemodialysis due to AL nephropathy. The median time from the diagnosis of amyloidosis to enrollment was 3.8 months (range: 0.76-16). Nine patients (15%) had received earlier treatment with oral melphalan and prednisone, high-dose pulse dexamethasone or combination infusional chemotherapy with vincristine, adriamycin and dexamethasone (VAD) and had persistence of a plasma cell dyscrasia.
Treatment experience
Of the 62 patients enrolled, nine (15%) were removed from the protocol because of either inadequate stem cell collection of o7.5 Â 10 6 CD34 þ /kg (n ¼ 7, 11%), or complications during stem cell mobilization and collection (n ¼ 2, 3%). One patient developed spontaneous rupture of the spleen during G-CSF mobilization, 8 and the other developed hyperbilirubinemia.
Fifty-three patients (85%) received a first cycle of HDM at 200 mg/m 2 and SCT under the protocol. Of note, two patients on hemodialysis due to renal failure received the first cycle of HDM also at 200 mg/m 2 . There were four deaths (8%) within 100 days of the first HDM/SCT. Of 49 evaluable patients, 27 (55%) patients achieved an HCR at 6 months after the first cycle of HDM/SCT.
Of the 22 patients without an HCR at 6 months, 17 patients (77%) received a second cycle of HDM/SCT, while five patients did not either because of patient choice (n ¼ 4) or because of excessive non-hematologic toxicities during the first cycle of treatment (n ¼ 1). There was one death (6%) within 100 days after the second cycle of HDM/SCT.
Treatment-related toxicity
Treatment-related mortality (TRM), defined as deaths occurring within 100 days of HDM/SCT, was comparable to those reported by us and others in previous large series. 3, [9] [10] [11] There were no deaths during the stem cell mobilization and collection phase of treatment and the overall early death rate within 100 days of SCT was 9% (n ¼ 5/53) (Table 1a) .
Grade IV non-hematologic toxicities occurred in 25% (13/53) of patients after the first cycle of HDM/SCT. Grade IV non-hematologic toxicities occurred in 24% (4/17) patients after the second cycle of HDM/SCT (Table 1b) . Of note are the episodes of culture-negative fever that occurred on the days of second cycle of melphalan infusion in 6 (35%) patients. This did not occur in the first cycle of HDM/SCT in this series or in more than 400 other patients treated with a single cycle of HDM/SCT. It was characterized by temperatures of 101-1031F (38.3-39.41C), usually beginning the evening of the first day of melphalan, and persisting for up to 48 h. Some patients were treated briefly with antibiotics at the discretion of the treating physician for the treatment of the possibility of bacteremia associated with the central venous catheter, but no positive-cultures were obtained.
Of clinical interest, a bacterial sepsis syndrome was more common after the second cycle of HDM/SCT (12%) than after the first cycle of treatment (4%) (P ¼ 0.19, w 2 test).
Hematologic response
After the second cycle of HDM/SCT, 5 of 16 (31%) surviving patients, who had evidence of a persistent plasma cell dyscrasia following the initial cycle of HDM/SCT, achieved an HCR. This was in addition to the 27 patients (55% of the 49 patients who completed initial treatment on the protocol), who had achieved an HCR after the first cycle of HDM/SCT. Thus, the ultimate HCR rate on this trial was 67% for surviving patients in whom treatment response could be assessed (32/48), and 60% (32/53) for all patients who completed initial treatment in this trial. Of the 17 patients who did not achieve an HCR after the first cycle of HDM/SCT and underwent a second cycle of Table 1a Causes of treatment-related mortality
Causes
First cycle of HDM/SCT (n ¼ 4/53, 8%)
Diffuse interstitial pneumonitis, sudden cardiac death, pulmonary embolism, sever GI bleeding Second cycle of HDM/SCT (n ¼ 1/17, 6%) Parainfluenza 3 viral pneumonia Abbreviation: HDM/SCT ¼ high-dose melphalan and stem cell transplantation.
Table 1b
Grade IV non-hematologic treatment-related adverse events Tandem HDM/SCT in AL amyloidosis V Sanchorawala et al HDM/SCT, nine had achieved a partial response and eight had achieved a stable hematologic response. The five patients who achieved an HCR after the second cycle of HDM/SCT had not achieved a hematologic partial response after the first cycle. In two of the five patients monoclonal gammopathy had disappeared from the serum but not from the urine by IFE after the first cycle. Unfortunately, serum-free light chain assay was not available in the first three patients after the first HDM/ SCT and the other two patients had normal free light chain ratio before first HDM/SCT.
Durability of hematologic response
With a median follow-up of 43 months, 2 (6%) of 32 patients achieving an HCR have relapsed. One patient who had achieved an HCR after the first cycle had evidence of hematologic relapse at 24 months after the first cycle of HDM/SCT with clinical relapse at 60 months. The other patient had achieved an HCR after the second cycle and had evidence of hematologic relapse at 24 months with clinical relapse at 30 months. Both these patients have received additional treatments with lenalidomide and bortezomib and are alive and doing well.
Clinical response
Clinical response was measured at 6 months and annually following treatment for all surviving patients. Improvements were measured for all systems with a potential to improve, including renal, cardiac, liver and peripheral or autonomic neuropathy, and for performance status that was worse than a Southwest Oncology Group (SWOG) score of 1 at the time of initial evaluation. 7 Forty-nine patients were evaluable for clinical response after first and/ or second cycle of HDM/SCT. Of these 49 patients, 32 (65%) had clinical/organ response in at least one involved organ system. Clinical responses were more evident among patients, who achieved an HCR (24/32, 75%), than among those who did not (8/32, 25%) (P ¼ 0.002). The details of clinical response are summarized in Table 2 .
Survival
The median survival for all 62 patients enrolled in the trial, has not yet been reached with a median follow-up of 43 months (range: 18-74). This survival compares favorably with a control cohort of 131 patients, similar in age, number of organ involvement and presence of severity of cardiac involvement and treated with a single cycle of 200 mg/m 2 of HDM/SCT on earlier clinical trials (P ¼ 0.042, log-rank test). The estimated median survival for the control cohort is 93.7 months (Figure 2 ).
Outcome of patients removed from the treatment protocol Of 62 patients enrolled, nine patients were removed from the treatment protocol. Of the seven patients with suboptimal stem cell collection, two had received earlier treatments with oral melphalan and prednisone and combination infusional chemotherapy (VAD). Of these nine excluded patients, three received one cycle of 200 mg/ m 2 HDM/SCT off protocol, and all three achieved an HCR and are well. Five of the nine excluded patients received modified HDM/SCT at 140 mg/m 2 and of these, only one patient remains alive to date. The patient with hyperbilirubinemia during G-CSF mobilization and collection was treated with oral melphalan and died from liver failure within 4 months.
Outcome of the patients who refused a second cycle of HDM/SCT Of the 22 patients who did not achieve an HCR, four patients refused to undergo a second cycle of HDM/SCT for personal reasons and one patient was not offered a second cycle due to unexpected grade IV non-hematologic toxicity (spontaneous pneumothorax) during the first cycle. Of these five patients, four patients survived and two received additional treatments with lenalidomide or thalidomide.
Discussion
We have found that treatment with tandem cycles of HDM/SCT is feasible and tolerable for selected patients Table 2 Clinical response Tandem HDM/SCT in AL amyloidosis V Sanchorawala et al with AL amyloidosis. This approach increases the proportion of patients who ultimately achieve an HCR and appears to be associated with an improvement in overall survival compared to a cohort of control cases treated with a single cycle of HDM/SCT. Longer follow-up will be required, however, to assess the ultimate benefit of tandem HDM/SCT with respect to survival of the patients treated in this trial. The TRM observed in this trial was lower than that reported in our previous trials, 3, 12 and this difference may be due to patient selection and improvement in supportive care. Of note, the upper age limit on this trial was 65 compared to our other reports where upper age limit was 80 years. 3 There were no deaths encountered during the stem cell mobilization and collection phase of treatment. Treatment-related adverse events were not excessive. Immediately following the melphalan administration for the second cycle of HDM/SCT, 6 (35%) patients had a syndrome of culture-negative fever that we refer to as a 'melphalan recall reaction', which appeared to be a hypersensitivity or chemical reaction, and not an infection. This type of reaction is not noted in the tandem cycles of melphalan with transplantation in myeloma. It is our speculation that this reaction is cytokine-mediated and was self-limiting in all cases. Of note, a bacterial sepsis syndrome was more common after the second cycle of HDM/SCT than after the first cycle, suggesting a persistent deficiency of host defenses following the initial cycle of treatment, although the incidence was not statistically significantly different.
Tandem cycles of HDM/SCT induced an HCR in 67% (32/48) of patients who could be evaluated for treatment response and 60% (32/53) for all patients who began a first cycle of HDM/SCT. This HCR rate is substantially higher than that observed with a single cycle of HDM/SCT (42%), 3 with a combination of oral melphalan and dexamethasone (33%) 13 and with lenalidomide and dexamethasone (29%). 14, 15 For all 62 patients enrolling in the trial, the HCR rate was 56% (35/62) by intention-to-treat, as three additional patients achieved an HCR with one cycle of HDM/SCT after being removed from the tandem treatment protocol. Thus, for patients who can tolerate this treatment approach, such treatment appears to result in the highest HCR rate of any treatment for AL amyloidosis reported to date. Furthermore, these HCRs were, as expected, associated with improvements in organ dysfunction caused by amyloid disease, and it is noteworthy that seven patients (44% of those who received two cycles of HDM/SCT) experienced a clear clinical response only after the second cycle of treatment. Nonetheless, this group of 17 patients undergoing a second cycle of HDM/SCT is quite small and the morbidity, mortality and financial and social issues associated with the second cycle should be balanced with other novel agents.
The optimal timing of a second cycle of HDM/SCT is not clear. As observed with the 'Total Therapy 1' treatment for myeloma (the first tandem autotransplant protocol studied in newly diagnosed patients with multiple myeloma) the overall and event-free survival at 15 years was 17 and 7% respectively. 16 A multivariate analysis indicated that most surviving patients on this trial completed two cycles of HDM/SCT within 12 months (P ¼ 0.019). Therefore, we designed this trial to offer the second cycle of HDM/SCT within 6-12 months of the first cycle. Moreover, the hematologic responses could occur late after HDM/SCT in patients with AL amyloidosis and, additionally, these patients do require a longer time to recover from the toxicities of first cycle of HDM/SCT than patients with myeloma.
The optimal dose of a second cycle of HDM is not clear. Two patients on a pilot study of tandem cycles of HDM/ SCT received 200 mg/m 2 for the second cycle at our institution and developed significant grade IV non-hematologic toxicities, requiring prolonged intensive-care unit stay. Because of these adverse events, this study was designed to deliver a second cycle at a modified high dose at 140 mg/m 2 of melphalan. The goal of this dosing schedule was to deliver higher than 200 mg/m 2 of melphalan in a predefined period of time for patients who had evidence of a persistent plasma cell dyscrasia after the first cycle of HDM/SCT.
The optimal dose of stem cell collection to support two cycles of HDM is not clear. Although 2-2.5 Â 10 6 CD34 þ / kg is adequate for hematopoietic rescue to support HDM, we have preferred 4-5 Â 10 6 CD34 þ /kg to ensure quicker engraftment in these critically ill patients with multisystem involvement. However, we recognize that the optimal dose of stem cell collection remains controversial.
A comparison analysis indicates that the tandem approach offers an improved survival. However, potential limitations of this comparison are shorter follow-up in the current study, lower TRM, patient selection, improvement in supportive care and possible impact of newer therapeutic regimens at the time of relapse. Therefore, this comparison should be viewed with keeping these limitations in mind. These groups will be followed to see if these survival curves remain separate. The availability of new agents for treatment of AL amyloidosis, thalidomide, [17] [18] [19] lenalidomide 14, 15 and others, may provide additional treatment options for patients with non-HCR after the first cycle of HDM/SCT in the future. Timing and sequencing of regimens containing these agents, and comparison to or combination with one or two cycles of HDM/SCT, will be determined in future trials.
